The BTA started out as the British Psychedelic Association, so our alliance towards the current research and evidential benefits of psychedelic assisted therapy remains a main priority. However, the bridge from the psychedelic world over to the worlds of education and legal mental health therapy are yet to be built. Therefore, the incorporation of transpersonal psychology will allow us to progress towards an all-encompassing view of how consciousness expansion, in its many forms including: breathwork, meditation, music, the arts, lucid dreaming, hypnosis and, of course, psychedelic experiences, can help people to heal from mental anguish. We are confident that transpersonal psychology will provide this much-needed broader approach.
The Wiley Blackwell Handbook of Transpersonal Psychology (Chapter 19-p.362, Psychedelic-Induced Experiences) states:
What can transpersonal psychology offer observational and experimental psychedelic science? First, transpersonal psychology’s interest in non-ordinary states, and in bringing to bear on psychology the insights from spiritual and indigenous traditions of many cultures, informs a broad context within which psychedelic research can be seen as indispensable. The Western assumption that only one state of mind reflects reality is typical of a monophasic culture; by contrast, it is likely that the majority of the world’s cultures are polyphasic, recognizing that different states of consciousness contribute to the perception of reality.
Transpersonal psychology is able to contribute to rigorous scientific research into the various impacts of psychedelic experience, but it is also able to design and interpret research from a perspective that considers these experiences as something more than delusional.
News & Research
An emerging solution for people who are challenged by disconnection, which severely impacts their mental health, could be the resurgence of ancient plant medicines such as psilocybin.
Recent research from Imperial College and Kings College in London and Johns Hopkins in the US, are demonstrating that psilocybin along with other psychedelics have a valuable role in the treatment of mental health and combatting addictions, which will revolutionize psychiatry.
In 2018 the FDA granted psilocybin and MDMA the status of a 'breakthrough therapy'. The state of Oregon legalised psilocybin in November 2020 for use in a therapeutic setting which paves the way for other states to follow. This will usher in capital investment in psychedelic therapy and pharmacology to an estimated amount of $2bn over the next year.
Here in the UK, Imperial College and Kings College have seen amazing results from their trials and the first psychedelic-assisted psychotherapy clinic opens soon in Bristol.
Article by Carhart-Harris:
We can no longer ignore the potential of psychedelic drugs to treat depression
At Imperial College we’ve been comparing psilocybin to conventional antidepressants – and the results are likely to be game-changing.
The impact of successful psychedelic therapy is often one of revelation or epiphany. People speak of witnessing “the bigger picture”, placing things in perspective, accessing deep insight about themselves and the world, releasing pent-up mental pain, feeling emotionally and physically recalibrated, clear-sighted and equanimous.